TSH Biopharm Valuation
Is 8432 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 8432 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 8432 (NT$59.5) is trading above our estimate of fair value (NT$21.58)
Significantly Below Fair Value: 8432 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8432?
Other financial metrics that can be useful for relative valuation.
| What is 8432's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | NT$2.28b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.1x |
| Enterprise Value/EBITDA | 21.6x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 8432's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 43.1x | ||
6817 Winston Medical Supply | 14.9x | n/a | NT$2.4b |
4747 Johnson Chemical Pharmaceutical Works | 40.8x | n/a | NT$3.3b |
4102 Yung Zip Chemical Ind | 26.2x | n/a | NT$1.6b |
4130 Genovate Biotechnology | 90.6x | n/a | NT$2.7b |
8432 TSH Biopharm | 36.9x | n/a | NT$2.3b |
Price-To-Earnings vs Peers: 8432 is good value based on its Price-To-Earnings Ratio (36.9x) compared to the peer average (43.1x).
Price to Earnings Ratio vs Industry
How does 8432's PE Ratio compare vs other companies in the TW Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 8432 is expensive based on its Price-To-Earnings Ratio (36.9x) compared to the TW Pharmaceuticals industry average (25.1x).
Price to Earnings Ratio vs Fair Ratio
What is 8432's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 36.9x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 8432's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.